Pulse Explorer nav.journalClub Débats Tendances Chercheurs Revues

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Accueil Explorer nav.journalClub Tendances

⌘+K

The 340B Drug Pricing Program at a Crossroads | Synapse

May 20, 2026JAMA0 citations

View Full Paper

The 340B Drug Pricing Program at a Crossroads

RKRyan P. KnoxDePaul University ASAmeet SarpatwariBrigham and Women's Hospital

Key Points

This viewpoint aims to highlight the history and current challenges of the 340B Drug Pricing Program and its implications for healthcare access.
Presents historical context of the 340B Drug Pricing Program
Summarizes controversies and limitations
Calls for congressional action and HRSA recommendations
Identifies significant controversies surrounding the program
Highlights limitations affecting safety-net hospitals and clinics
Encourages action from Congress and HRSA to enhance program effectiveness

Abstract

This Viewpoint presents the history of the Health Resources amp; Services Administration (HRSA) 340B Drug Pricing Program and 340B Rebate Model Pilot Program, summarizes their controversies and limitations, and calls for action by Congress and HRSA to address these issues and strengthen support for safety-net hospitals and clinics.

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Knox et al. (Mon,) studied this question.

synapsesocial.com/papers/6a0d50f3f03e14405aa9d23e https://doi.org/https://doi.org/10.1001/jama.2026.6812